Tocilizumab

被引：92
作者：
Venkiteshwaran, Adith [1 ]
机构：
[1] Rensselaer Polytech Inst, Troy, NY 12180 USA
来源：
MABS | 2009年 / 1卷 / 05期
关键词：
rheumatoid arthritis; Crohn disease; Castleman disease; IL-6; receptor; tocilizumab; interleukins for rheumatoid arthritis; IL-6 RECEPTOR INHIBITION; RHEUMATOID-ARTHRITIS; INADEQUATE RESPONSE; DISEASE-ACTIVITY; TNF-ALPHA; ANTIBODY; MONOTHERAPY; THERAPY; TRIAL;
D O I：
10.4161/mabs.1.5.9497
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interieukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocilizumab is marketed in Japan for Castleman disease and several types of arthritis. The product is approved in the European Union for treatment of moderate-to-severe rheumatoid arthritis, and is currently undergoing review by the US Food and Drug Administration for this condition. Tocilizumab has also been studied for potential use in the treatment of other IL-6 related disorders including Crohn disease.
引用
收藏
页码：432 / 438
页数：7
相关论文
共 21 条
[1]  
AGRAWAL S, 2007, NAT BIOTECHNOL, V25, P1094
[2]   Involvement of IL-6, apart from its role in immunity, in mediating a chronic response during experimental arthritis [J].
de Hooge, ASK ;
van de Loo, FAJ ;
Arntz, OJ ;
van den Berg, WB .
AMERICAN JOURNAL OF PATHOLOGY, 2000, 157 (06) :2081-2091
[3]   IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial [J].
Emery, P. ;
Keystone, E. ;
Tony, H. P. ;
Cantagrel, A. ;
van Vollenhoven, R. ;
Sanchez, A. ;
Alecock, E. ;
Lee, J. ;
Kremer, J. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (11) :1516-1523
[4]   Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J].
Feldmann, M ;
Maini, RN .
ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :163-196
[5]   Interleukin-6 Receptor Inhibition With Tocilizumab Reduces Disease Activity in Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Antirheumatic Drugs The Tocilizumab in Combination With Traditional Disease-Modifying Antirheumatic Drug Therapy Study [J].
Genovese, Mark C. ;
McKay, James D. ;
Nasonov, Evgeny L. ;
Mysler, Eduardo F. ;
da Silva, Nilzio A. ;
Alecock, Emma ;
Woodworth, Thasia ;
Gomez-Rein, Juan J. .
ARTHRITIS AND RHEUMATISM, 2008, 58 (10) :2968-2980
[6]   Distinct contribution of IL-6, TNF-α, IL-1, and IL-10 to T cell-mediated spontaneous autoimmune arthritis in mice [J].
Hata, H ;
Sakaguchi, N ;
Yoshitomi, H ;
Iwakura, Y ;
Sekikawa, K ;
Azuma, Y ;
Kanai, C ;
Moriizumi, E ;
Nomura, T ;
Nakamura, T ;
Sakaguchi, S .
JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (04) :582-588
[7]   A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease [J].
Ito, H ;
Takazoe, M ;
Fukuda, Y ;
Hibi, T ;
Kusugami, K ;
Andoh, A ;
Matsumoto, T ;
Yamamura, T ;
Azuma, J ;
Nishimoto, N ;
Yoshizaki, K ;
Shimoyama, T ;
Kishimoto, T .
GASTROENTEROLOGY, 2004, 126 (04) :989-996
[8]  
JONES G, 2009, ANN RHEUM D IN PRESS
[9]   Evolving knowledge and therapy of inflammatory bowel disease [J].
Korzenik, JR ;
Podolsky, DK .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (03) :197-209
[10]  
KREMER JM, 2008, AM COLL RHEUM ANN M
123